Organic Chemical – Page 4

Pfizer and Arvinas Abandon Commercialization of PROTAC Inhibitor, Triggering Layoffs and Pipeline Refocus

1 month ago talkbio0Tagged Arvinas, CDK inhibitors, layoffs, Malignant neoplasm of breast, Neoplasms, Pfizer, Protac, United States Food and Drug Administration, Vepdegestrant

Pfizer; Arvinas; PROTAC; vepdegestrant; layoffs; out-licensing; FDA; breast cancer; oncology; CDK inhibitors

Priovant Announces Successful Phase III Results for Brepocitinib in Dermatomyositis (VALOR Study)

1 month ago talkbio0Tagged Brepocitinib, Clinical Trials, cutaneous remission, Dermatomyositis, NDA filing, Phase III, Priovant, Roivant, Steroids, Total Improvement Score, Tumor stage Tis, VALOR study

Priovant; Roivant; brepocitinib; Phase III; VALOR study; dermatomyositis; clinical trial; Total Improvement Score; TIS; steroid reduction; cutaneous remission; NDA filing

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

1 month ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

1 month ago talkbio0Tagged Ang2, Biosciences, Clinical Trials, Disorder of eye, Macular edema due to diabetes mellitus, Ollin, OLN324, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A, Wet AMD

Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

1 month ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval

FDA Crackdown on Pharma TV Ads Targets Pfizer, Novartis, BMS, Lilly & Others

1 month ago talkbio0Tagged Burning Mouth Syndrome, Cautionary Warning, Correspondence as Topic, Crackdown, Direct-to-Consumer, drug marketing compliance, Eli Lilly, Novartis, Pfizer, pharma TV ads, provision, Sufficient, United States Food and Drug Administration

FDA crackdown; pharma TV ads; Pfizer; Novartis; BMS; Lilly; warning letters; direct-to-consumer advertising; adequate provision rule; drug marketing compliance

Areteia Therapeutics Posts Phase 3 Win for Oral Asthma Drug Dexpramipexole

1 month ago talkbio0Tagged Areteia, biologic blockbusters, Dexpramipexole, EXHALE-4, oral asthma therapy, Phase 3, Pulmonary Eosinophilia, topline

Areteia Therapeutics; dexpramipexole; Phase 3; oral asthma therapy; biologic blockbusters; eosinophilic asthma; EXHALE-4; topline results

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

1 month ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal

1 month ago talkbio0Tagged AI/ML-enabled product, Collaboration, Drug Discovery, engine, immune-mediated diseases, milestone payments, molecular glue degraders, Monte Rosa Therapeutics, MRT-6160, Novartis, VAV1 protein

Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine

AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S.

1 month ago talkbio0Tagged AbbVie, exclusivity extension, Generic competition, Market, Patent Settlement, pharmaceutical litigation, Rinvoq, U.S., upadacitinib

AbbVie; Rinvoq; patent settlement; generic competition; exclusivity extension; upadacitinib; US market; pharmaceutical litigation